Victory Capital Management
VNDA icon

Victory Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Victory Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-216,717
Closed -$891K – 2540
2024
Q1 		$891K Buy
216,717
+91,391
+73% +$366K ﹤0.01% 1794
2023
Q4 		$529K Sell
125,326
-21,712
-15% -$87.6K ﹤0.01% 1982
2023
Q3 		$635K Sell
147,038
-3,363
-2% -$18.7K ﹤0.01% 1879
2023
Q2 		$991K Sell
150,401
-85,243
-36% -$546K ﹤0.01% 1684
2023
Q1 		$1.6M Sell
235,644
-43,409
-16% -$305K ﹤0.01% 1471
2022
Q4 		$2.06M Sell
279,053
-13,187
-5% -$128K ﹤0.01% 1426
2022
Q3 		$2.89M Buy
292,240
+18,325
+7% +$193K ﹤0.01% 1371
2022
Q2 		$2.99M Buy
273,915
+15,334
+6% +$159K ﹤0.01% 1360
2022
Q1 		$2.83M Sell
258,581
-2,106
-0.8% -$27.7K ﹤0.01% 1398
2021
Q4 		$4.09M Buy
260,687
+5,202
+2% +$90.6K ﹤0.01% 1377
2021
Q3 		$4.38M Buy
255,485
+119,259
+88% +$2.09M ﹤0.01% 1368
2021
Q2 		$2.93M Buy
136,226
+84,772
+165% +$1.52M ﹤0.01% 1520
2021
Q1 		$773K Buy
51,454
+26,585
+107% +$430K ﹤0.01% 2024
2020
Q4 		$327K Buy
24,869
+7,249
+41% +$87.3K ﹤0.01% 2255
2020
Q3 		$170K Buy
+17,620
New +$188K ﹤0.01% 2304
2020
Q2 		– Sell
-14,684
Closed -$152K – 3277
2020
Q1 		$152K Buy
14,684
+4,494
+44% +$55.7K ﹤0.01% 2404
2019
Q4 		$167K Buy
10,190
+2,084
+26% +$31.5K ﹤0.01% 2364
2019
Q3 		$108K Buy
8,106
+5,242
+183% +$73.1K ﹤0.01% 2412
2019
Q2 		$40K Sell
2,864
-4,978
-63% -$79.2K ﹤0.01% 1760
2019
Q1 		$144K Buy
+7,842
New +$179K ﹤0.01% 1626

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management's VNDA Position: Q2 2024 in Review

Victory Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2024, closing a stake of 216,717 shares — an estimated $891K sold.

Victory Capital Management first reported a position in VNDA in Q1 2019 and held it in 20 quarters. The position peaked at $4.38M in Q3 2021. 148 funds tracked by Wall St. Rank hold VNDA as of Q2 2024.

  • Victory Capital Management reported no remaining Vanda Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Victory Capital Management sold 216,717 Vanda Pharmaceuticals shares in Q2 2024, an estimated $891K.
  • Victory Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2019 and held it in 20 quarters.
  • Victory Capital Management's Vanda Pharmaceuticals position peaked at $4.38M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2024.

Based on Victory Capital Management's 13F filing for Q2 2024, filed 5 Aug 2024.